The better modality is the one that makes the weakest project assumption testable. Compare the evidence, discovery burden, cellular context, and development constraints before committing to a PROTAC or molecular glue program.
Specify the cell type, target isoform, required depth, onset, duration, reversibility, and functional consequence of protein removal.
Assess target ligands, exit vectors, ligase-binding scaffolds, phenotypic hits, structures, and available SAR.
Confirm protein abundance, localization, complex assembly, functional activity, and tissue-relevant constraints.
Connect binary engagement to ternary formation, ubiquitination, degradation, selectivity, and cellular exposure.
Advance the route that converts current knowledge into the clearest, fastest, and most discriminating experiments.
The modality choice should change the work plan. A PROTAC route benefits from testing component combinations and exposure liabilities early, whereas a molecular-glue route must rapidly establish the recruited partner and compound-dependent interface. The following entry points support distinct decisions rather than a single generic workflow.
| Criterion | PROTAC | Molecular glue |
|---|---|---|
| Typical starting evidence | Target ligand plus an E3 recruiter; attachment sites can be explored. | Phenotypic hit, known ligase-binding scaffold, or evidence of a ligand-stabilized interface. |
| Design logic | Modular assembly followed by ternary-complex and property optimization. | Interface induction or stabilization followed by mechanism and neosubstrate mapping. |
| Chemical space | Large and flexible, often beyond rule-of-five; the linker creates many coupled variables. | Usually more compact, but subtle substitutions can switch substrate recruitment. |
| Mechanistic discovery | The target and ligase are usually proposed before synthesis. | The recruited substrate or ligase can be unknown when the hit is identified. |
| Structural challenge | Sampling a flexible three-body system and multiple linker conformations. | Resolving weak, cooperative contacts at a shallow composite interface. |
| Primary risks | Permeability, solubility, conformational heterogeneity, hook effect, and synthesis burden. | Low hit rate, difficult deconvolution, neosubstrate selectivity, and interface-mediated resistance. |
| Best-fit capabilities | Medicinal chemistry, conjugate synthesis, ternary assays, exposure analysis, and structural modeling. | Phenotypic screening, genetics, proteomics, chemical biology, and structural deconvolution. |
Favor a PROTAC when the target has a cell-active ligand, one or more tolerated exit vectors, and a relevant E3 system that can be recruited with tractable chemistry.
Favor a molecular glue route when a phenotype is proteasome-dependent, a ligase-binding scaffold is known, or a shallow composite surface offers a credible recruitment hypothesis.
A time-boxed parallel study can prevent platform bias. Use common biological endpoints while testing different chemistry and mechanism assumptions for each route.
The sequence below prevents a strong result in one assay from hiding a failure in target biology, exposure, ligase context, or mechanism.
Discuss Your Study DesignDefine why degradation is preferable to inhibition. Compare acute protein loss with genetic depletion and determine whether scaffolding or non-catalytic functions matter.
For a PROTAC, confirm cellular engagement and attachment tolerance. For a glue, define the phenotypic, ligase, degron, or structural evidence that can seed discovery.
Measure active ligase context at the protein and functional levels, including localization, complex partners, disease state, and normal-tissue distribution.
Connect engagement and induced-complex formation to ubiquitination, target loss, selectivity, washout recovery, and target-proximal function.
Integrate free intracellular exposure, physicochemical behavior, neosubstrate risk, synthesis burden, desired tissue, and dosing objective before expanding chemistry.
PROTACs offer explicit design variables, but every change couples ternary geometry with molecular properties. A useful first matrix spans exit vectors, E3 systems, linker length, linker character, and mechanistic controls.
Compact chemistry can reduce some property risks, but biological interpretation is often harder. The program must be able to discover and validate the recruited substrate rather than infer it from phenotype alone.
Start with a PROTAC feasibility matrix across attachment site, E3 recruiter, and linker hypotheses.
Prioritize molecular glue mechanism deconvolution using early proteomics, resistance genetics, and induced-binding assays.
Screen analogs for selective neosubstrate recruitment and map structure–recruitment relationships.
Investigate permeability, free intracellular exposure, ubiquitination geometry, ligase activity, and target resynthesis.
Pause potency optimization and identify direct substrates, secondary effects, and the source of toxicity.
Do not force a modality. Build target and screening evidence before committing to PROTAC or glue chemistry.
Disease context, cell population, isoform, desired depletion kinetics, recovery, and target-proximal function.
Target ligands, ligase-binding scaffolds, phenotypic hits, exit vectors, SAR, purity, and matched controls.
E3 abundance and localization, engagement assays, ternary assays, proteomics, and genetic perturbation capacity.
Desired tissue and route, free intracellular exposure, selectivity expectations, timing, and predefined review criteria.
Structural examples clarify why neither binary affinity nor compound size alone determines the best modality.
The VHL–MZ1–BRD4 ternary structure showed how linker geometry and newly formed protein–protein contacts can stabilize a selective complex. The example supports ensemble-based ternary design but should not be treated as a universal geometry for other targets or ligases.
Systematic chemical profiling illustrates how molecular glue discovery can begin from cellular response and use genetic dependencies to identify the responsible degradation machinery. The discovery burden differs from modular PROTAC construction because the recruited substrate may not be known at hit identification.
These questions address assumptions that frequently push a project toward one platform before the supporting evidence is ready.
Their smaller size may reduce some permeability and formulation risks, but developability remains compound-specific. Molecular glues can recruit unexpected neosubstrates, show steep structure–activity changes, or require difficult mechanism deconvolution. Exposure, selectivity, metabolism, and safety still need direct measurement.
Potentially. A target may have a ligand suitable for PROTAC attachment and a surface capable of glue-mediated recognition. The programs would have different ligases, discovery burdens, selectivity profiles, and property risks. Parallel feasibility work can be useful when the value of target degradation is high.
Revisit it when the assumed bottleneck changes. Repeated PROTAC failure caused by exposure or exit-vector constraints may justify another chemistry strategy. A glue screen that yields phenotype without a tractable ligase–substrate mechanism may favor a defined PROTAC route. Decisions should follow evidence rather than platform commitment.
Share the target, known ligands, preferred or available E3 systems, phenotypic hits, structural data, assay capacity, and development constraints. CD ComputaBio can propose a staged comparison that tests the assumptions most likely to determine whether a PROTAC, molecular glue, or parallel route should advance.
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk
